A Phase III, Double-Blind, Placebo Controlled, Parallel Group, International, Multicenter Study of 12 Weeks Treatment with Trafermin 0.01% Spray in Patients with Diabetic Foot Ulcer of Neuropathic Origin The TRAfermin in Neuropathic diabetic foot ulcer Study - northern Europe (The TRANS-North study).

Trial Profile

A Phase III, Double-Blind, Placebo Controlled, Parallel Group, International, Multicenter Study of 12 Weeks Treatment with Trafermin 0.01% Spray in Patients with Diabetic Foot Ulcer of Neuropathic Origin The TRAfermin in Neuropathic diabetic foot ulcer Study - northern Europe (The TRANS-North study).

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Aug 2014

At a glance

  • Drugs Trafermin (Primary)
  • Indications Diabetic foot ulcer
  • Focus Biomarker; Therapeutic Use
  • Acronyms TRANS-North
  • Sponsors Olympus Biotech Europe SAS
  • Most Recent Events

    • 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Oct 2012 Planned end date changed from 1 Jan 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 09 Jun 2012 Company added in the association field as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top